within Pharmacolibrary.Drugs.V_Various.V03A_AllOtherTherapeuticProducts.V03AF02_Dexrazoxane;

model Dexrazoxane
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 8.847222222222222e-05,
    adminDuration = 600,
    adminMass = 500 / 1000000,
    adminCount = 1,
    Vd = 0.0013,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0028,
    k12 = 6.611111111111111e-05,
    k21 = 6.611111111111111e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Dexrazoxane</td></tr><tr><td>ATC code:</td><td>V03AF02</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>500</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>1.3</td><td>L</td></tr>
    <tr><td>clearance:</td><td>4.55</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Dexrazoxane is a cytoprotective agent used to reduce the incidence and severity of cardiotoxicity associated with anthracycline chemotherapy such as doxorubicin. It acts as a chelating agent, reducing free radical formation and preventing cardiac tissue damage. Dexrazoxane is approved for use in patients receiving high cumulative doses of anthracyclines.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters obtained from adult cancer patients receiving intravenous dexrazoxane before anthracycline chemotherapy.</p><h4>References</h4><ol><li><p>Cvetković, RS, &amp; Scott, LJ (2005). Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy. <i>Drugs</i> 65(7) 1005–1024. DOI:<a href=\"https://doi.org/10.2165/00003495-200565070-00008\">10.2165/00003495-200565070-00008</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15892593/\">https://pubmed.ncbi.nlm.nih.gov/15892593</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.V.V03AF02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Dexrazoxane;
